Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Opiant receives FDA feedback on development of OPNT-002 for alcohol use disorder

March 2, 2017

Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150

Feb. 23, 2017

FDA issues complete response letter for Amphastar's intranasal naloxone

Feb. 23, 2017

Adapt Pharma applies for E.U. approval of naloxone HCl nasal spray

Feb. 22, 2017

Amygdala Neurosciences acquires ALDH2 inhibitor from Gilead

Feb. 17, 2017

Chrysalis Biotherapeutics begins contract with NIAID for TP-508 as nuclear countermeasure

Feb. 9, 2017

GSK-598809 restores reward deficits in substance dependence

Jan. 18, 2017

TSRI, Icahn School of Medicine and UPenn patent nAChR modulators

Dec. 15, 2016

Promising phase III topline results for CAM-2038 to treat moderate to severe opioid use disorder

Nov. 14, 2016

Omeros reports on phase II trial of PPARgamma agonist in heroin-dependent subjects

Nov. 3, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....